Phase 2 Brain Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are able to understand the study and are willing to sign a written consent form
- People aged 2 to 70 years old
- People diagnosed with a returning or treatment-resistant brain tumour called diffuse midline glioma or diffuse intrinsic pontine glioma, confirmed to have a specific genetic change (H3K27M mutation), who have already received standard treatments such as surgery and radiation/chemotherapy
- People who are either not taking a steroid medication called dexamethasone, or are taking only a low dose (4 mg per day or less) at a specific point in the process
- People whose general health and ability to function meets a minimum level, as measured by a standard scoring tool (confirm with trial site)
- People with a life expectancy of more than 3 months
- People whose bone marrow, liver, and kidney are working well enough to meet specific blood test results (confirm with trial site for exact values)
- People whose blood contains enough of a certain type of immune cell (lymphocytes) to meet a minimum level
- People with satisfactory heart function
- People willing to follow the medical team's instructions throughout the study; women of childbearing age must have a negative pregnancy test within 7 days of starting, and both male and female participants of reproductive age must agree to use contraception during the study and for 3 months after it ends
Who may not be able to join:
- People who have had a specific type of chemotherapy wafer (gliadel) implanted within the 4 weeks before the study starts, or who are currently receiving antibody-based treatments
- People who are HIV positive
- People with tuberculosis that is not currently under control
- People with a history of an autoimmune disease, or any condition requiring long-term use of steroids or immune-suppressing medications
- People with a history of severe allergic disease, or known allergy to immune cells or the study treatment
- People already actively taking part in another immune cell clinical trial, or people the investigators believe may not be suitable or able to follow the study requirements
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: +86 0755-86573763
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Percentage of adverse effects after H3K27M-EIE injection
Can't join this trial?
Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.